Abstract
Rationale
Cannabinoids have recently been identified as potential neuronal modulators of pruritic response, representing a potential target in the treatment of itch associated with a variety of pathophysiologic conditions. While the selective CB1 receptor antagonist rimonabant is an established pruritic agent in both animal and clinical testing, its receptor mechanism of action and anatomical loci remain unclear.
Objective
The purpose of this study was to determine whether CB1 receptor blockade is critical to rimonabant-induced scratching and to identify differences in scratching response based on different routes of administration. Furthermore, experiments were designed to elucidate any evidence as to whether rimonabant elicits scratching behavior through common immunologic hypersensitivity mechanisms.
Results
Rimonabant was equally effective at producing scratching via intraperitoneal and local subcutaneous injection. This compound also produced an intense scratching response when administered intrathecally, but had no effects after intracerebroventricular administration. Repeated administration of rimonabant led to a decreased magnitude of scratching. While rimonabant-induced scratching was not attenuated either by pretreatment with the H1 receptor antagonist loratadine or in mast cell-deficient mice, it lacked efficacy in CB1 (−/−) mice.
Conclusions
Rimonabant is a potent and fully effective pruritogen when administered spinally or systemically and requires CB1 receptors to induce scratching, suggesting an important spinal CB1 receptor component of action. The lack of responsiveness to H1 antagonism or mast cell deficiency supports previous findings that cannabinoids modulate itch through neuronal mechanisms, and not by traditional hypersensitivity activation.
Similar content being viewed by others
Abbreviations
- FAAH:
-
Fatty acid amide hydrolase
- Rimonabant:
-
N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl
- THC:
-
Δ9-tetrahydrocannabinol
- ANOVA:
-
Analysis of variance
- icv:
-
Intracerebroventricular
- C57:
-
C57BL/6J mouse strain
- DRG:
-
Dorsal root ganglion
References
Allansmith MR, Baird RS, Ross RN, Barney NP, Bloch KJ (1987) Effect of multiple applications of compound 48/80 on mast cells of rat conjunctiva. Acta Ophthalmol Copenh 65:406–412
Ambrus LC, Thurber L (1975) Effect of cromolyn sodium and of daily exposure to compound 48/80 on experimental asthma. Res Commun Chem Pathol Pharmacol 11:491–494
Andrew D, Craig AD (2001) Spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch. Nat Neurosci 4:72–77
Best AR, Regehr WG (2008) Serotonin evokes endocannabinoid release and retrogradely suppresses excitatory synapses. J Neurosci 28:6508–6515
Cevikbas F, Steinhoff M, Ikoma A (2010) Role of spinal neurotransmitter receptors in itch: new insights into therapies and drug development. CNS Neurosci Ther (in press)
Cook SA, Lowe JA, Martin BR (1998) CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol. J Pharmacol Exp Ther 285:1150–1156
Darmani NA (2001) Cannabinoids of diverse structure inhibit two DOI-induced 5-HT(2A) receptor-mediated behaviors in mice. Pharmacol Biochem Behav 68:311–317
Darmani NA, Pandya DK (2000) Involvement of other neurotransmitters in behaviors induced by the cannabinoid CB1 receptor antagonist SR 141716A in naive mice. J Neural Transm 107:931–945
Darmani NA, Janoyan JJ, Kumar N, Crim JL (2003) Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover. Pharmacol Biochem Behav 75:777–787
Dvorak M, Watkinson A, McGlone F, Rukwied R (2003) Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. Inflamm Res 52:238–245
European Medicines Agency (2008) Accomplia: European public assessment reports. European Medicines Agency, London
Fitton AG, Pertwee RG (1982) Changes in body temperature and oxygen consumption rate of conscious mice produced by intrahypothalamic and intracerebroventricular injections of delta 9-tetrahydrocannabinol. Br J Pharmacol 75:409–414
Granberg M, Fowler CJ, Jacobsson SO (2001) Effects of the cannabimimetic fatty acid derivatives 2-arachidonoylglycerol, anandamide, palmitoylethanolamide and methanandamide upon IgE-dependent antigen-induced beta-hexosaminidase, serotonin and TNF alpha release from rat RBL-2 H3 basophilic leukaemic cells. Naunyn-Schmiedebergs Arch Pharmacol 364:66–73
Haller VL, Stevens DL, Welch SP (2008) Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase. Eur J Pharmacol 600:50–58
Hylden JL, Wilcox GL (1983) Pharmacological characterization of substance P-induced nociception in mice: modulation by opioid and noradrenergic agonists at the spinal level. J Pharmacol Exp Ther 226:398–404
Inagaki N, Igeta K, Kim JF, Nagao M, Shiraishi N, Nakamura N, Nagai H (2002) Involvement of unique mechanisms in the induction of scratching behavior in BALB/c mice by compound 48/80. Eur J Pharmacol 448:175–183
Janoyan JJ, Crim JL, Darmani NA (2002) Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids. Pharmacol Biochem Behav 71:155–162
Jarbe TU, LeMay BJ, Olszewska T, Vemuri VK, Wood JT, Makriyannis A (2008) Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats. Pharmacol Biochem Behav 91:84–90
Karsak M, Gaffal E, Date R, Wang-Eckhardt L, Rehnelt J, Petrosino S, Starowicz K, Steuder R, Schlicker E, Cravatt B, Mechoulam R, Buettner R, Werner S, Di Marzo V, Tuting T, Zimmer A (2007) Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 316:1494–1497
Kelly S, Donaldson LF (2008) Peripheral cannabinoid CB1 receptors inhibit evoked responses of nociceptive neurones in vivo. Eur J Pharmacol 586:160–163
Landsman RS, Burkey TH, Consroe P, Roeske WR, Yamamura HI (1997) SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur J Pharmacol 334:R1–R2
Moranta D, Esteban S, Garcia-Sevilla JA (2009) Chronic treatment and withdrawal of the cannabinoid agonist WIN 55, 212–2 modulate the sensitivity of presynaptic receptors involved in the regulation of monoamine syntheses in rat brain. Naunyn Schmiedebergs Arch Pharmacol 379:61–72
Ohtsuki H, Takeuchi K, Okabe S (1985) Effects of prolonged treatment with compound 48/80 on the gastric mucosa and mast cells in the rat. Jpn J Pharmacol 38:195–198
Pedigo NW, Dewey WL, Harris LS (1975) Determination and characterization of the antinociceptive activity of intraventricularly administered acetylcholine in mice. J Pharmacol Exp Ther 193:845–852
Richardson JD, Kilo S, Hargreaves KM (1998) Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75:111–119
Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240–244
Rubino T, Vigano D, Zagato E, Sala M, Parolaro D (2000) In vivo characterization of the specific cannabinoid receptor antagonist, SR141716A: behavioral and cellular responses after acute and chronic treatments. Synapse 35:8–14
Rutkowska M, Gliniak H (2009) The influence of ACEA—a selective cannabinoid CB1 receptor agonist on whole blood and platelet-poor plasma serotonin concentrations. Pharmazie 64:598–601
Schlosburg JE, Boger DL, Cravatt BF, Lichtman AH (2009) Endocannabinoid modulation of scratching response in an acute allergenic model: a new prospective neural therapeutic target for pruritus. J Pharmacol Exp Ther 329:314–323
Schmeling WT, Hosko MJ (1980) Effect of delta 9-tetrahydrocannabinol on hypothalamic thermosensitive units. Brain Res 187:431–442
Seyrek M, Kahraman S, Deveci MS, Yesilyurt O, Dogrul A (2010) Systemic cannabinoids produce CB-mediated antinociception by activation of descending serotonergic pathways that act upon spinal 5-HT and 5-HT(2A) receptors. Eur J Pharmacol 649:183–194
Sim-Selley LJ, Brunk LK, Selley DE (2001) Inhibitory effects of SR141716A on G-protein activation in rat brain. Eur J Pharmacol 414:135–143
Sugimoto Y, Umakoshi K, Nojiri N, Kamei C (1998) Effects of histamine H1 receptor antagonists on compound 48/80-induced scratching behavior in mice. Eur J Pharmacol 351:1–5
Sun YG, Zhao ZQ, Meng XL, Yin J, Liu XY, Chen ZF (2009) Cellular basis of itch sensation. Science 325:1531–1534
Tallett AJ, Blundell JE, Rodgers RJ (2007) Grooming, scratching and feeding: role of response competition in acute anorectic response to rimonabant in male rats. Psychopharmacol Berl 195:27–39
Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP, Witkin JM, Nomikos GG (2003) The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 138:544–553
Vaccarino FJ, Pettit HO, Bloom FE, Koob GF (1985) Effects of intracerebroventricular administration of methyl naloxonium chloride on heroin self-administration in the rat. Pharmacol Biochem Behav 23:495–498
Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA (2003) Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacol Berl 167:103–111
Wada T, Ishiwata K, Koseki H, Ishikura T, Ugajin T, Ohnuma N, Obata K, Ishikawa R, Yoshikawa S, Mukai K, Kawano Y, Minegishi Y, Yokozeki H, Watanabe N, Karasuyama H (2010) Selective ablation of basophils in mice reveals their nonredundant role in acquired immunity against ticks. J Clin Invest 120:2867–2875
Ward L, Wright E, McMahon SB (1996) A comparison of the effects of noxious and innocuous counterstimuli on experimentally induced itch and pain. Pain 64:129–138
Ward SJ, Lefever TW, Rawls SM, Whiteside GT, Walker EA (2009) Age-dependent effects of the cannabinoid CB1 antagonist SR141716A on food intake, body weight change, and pruritus in rats. Psychopharmacol Berl 206:155–165
Welch SP, Huffman JW, Lowe J (1998) Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J Pharmacol Exp Ther 286:1301–1308
Yamazaki M, Tsujimura T, Morii E, Isozaki K, Onoue H, Nomura S, Kitamura Y (1994) C-kit gene is expressed by skin mast cells in embryos but not in puppies of Wsh/Wsh mice: age-dependent abolishment of c-kit gene expression. Blood 83:3509–3516
Yosipovitch G, Duque MI, Fast K, Dawn AG, Coghill RC (2007) Scratching and noxious heat stimuli inhibit itch in humans: a psychophysical study. Br J Dermatol 156:629–634
Yosipovitch G, Fast K, Bernhard JD (2005) Noxious heat and scratching decrease histamine-induced itch and skin blood flow. J Investig Dermatol 125:1268–1272
Zhang G, Chen W, Lao L, Marvizon JC (2010) Cannabinoid CB1 receptor facilitation of substance P release in the rat spinal cord, measured as neurokinin 1 receptor internalization. Eur J Neurosci 31:225–237
Acknowledgments
The work was supported by P01DA009789 P50DA005274, RO1AI18697, and R01DA015197. Training of author JES was supported by National Institute of Drug Abuse grant F31DA026279 and T32DA007027.
Conflicts of interest
The authors report no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schlosburg, J.E., O’Neal, S.T., Conrad, D.H. et al. CB1 receptors mediate rimonabant-induced pruritic responses in mice: investigation of locus of action. Psychopharmacology 216, 323–331 (2011). https://doi.org/10.1007/s00213-011-2224-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-011-2224-5